Nav: Home

Adding vemurafenib doubles progression-free survival in BRAF metastatic colorectal cancer

June 05, 2017

Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) to treatment with cetuximab and irinotecan (anti-EGFR) in patients with metastatic colorectal cancer that have a BRAF V600E mutation. In the randomized trial, 49 patients who received vemurafenib in combination with cetuximab and irinotecan showed median 4.3 months progression-free survival (PFS), compared with 2.0 months median PFS for 50 patients given cetuximab and irinotecan alone. Disease control rate was 67 percent for the combination including vemurafenib versus 22 percent for the two-drug combination. Overall survival was median 5.9 months for the two-drug combination and 9.6 months with the addition of vemurafenib. The study implies that inhibiting BRAF along with EGFR in this population may be more potent than inhibiting either of these targets alone.

"The 5-10 percent of patients with metastatic colorectal cancer that have a BRAF V600E mutation tend to have a significantly worse prognosis than patients who do not have this mutation," explains Chris Lieu, MD, director of the University of Colorado Cancer Center Colorectal Medical Oncology Program. "This is a group of patients that clearly need better treatment options, and this study is a very positive step in the right direction."

The discovery takes place in a mutational landscape that can be seen as a musical mixing board. Alone, vemurafenib turns down BRAF but often at the expense of turning up the gene EGFR, which is involved in controlling the rate of cell replication (a hallmark of cancer). Preclinical work by Lieu and colleagues shows that this upregulation of EGFR in response to BRAF inhibition may be one reason that BRAF inhibitors alone have not been especially successful in treating colorectal tumors.

"This laboratory research showing that EGFR upregulation is a resistance mechanism of colorectal cancer to BRAF targeted therapy led to the development of this trial," says Lieu. "This is truly a success of what we consider bench-to-bedside research."

In the study, 99 patients were given the common colorectal cancer treatment of the chemotherapy irinotecan with the anti-EGFR therapy cetuximab, with half adding the BRAF inhibitor vemurafenib. This study allowed crossover in which patients who were not randomized to receive vemurafenib were allowed to receive the combination of all three drugs at the time that their tumor grew. Fifty percent of patients who were enrolled onto the trial crossed over and received the three-drug study regimen.

"These results and others demonstrate that recent successes in genetically targeted therapies may be only a first step toward the best clinical use of these therapies," Lieu says. "Now, the challenge is to combine, sequence and prescribe these therapies with the most rational strategies to the patient populations most likely to benefit."
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...